XNASTRDA
Market cap458mUSD
Jan 15, Last price
12.25USD
1D
-1.92%
1Q
-30.52%
IPO
-45.58%
Name
Entrada Therapeutics Inc
Chart & Performance
P/E
—
P/S
3.55
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
129m
Net income
-7m
L-92.36%
CFO
140m
P
Earnings
Jun 13, 2025
Profile
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 129,013 | ||||
Cost of revenue | 232,059 | 99,143 | |||
Unusual Expense (Income) | |||||
NOPBT | (103,046) | (99,143) | |||
NOPBT Margin | |||||
Operating Taxes | 18,741 | (7,159) | |||
Tax Rate | |||||
NOPAT | (121,787) | (91,984) | |||
Net income | (6,685) -92.36% | (87,457) 74.66% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 19,407 | 763 | |||
BB yield | -3.89% | -0.18% | |||
| Debt | |||||
Debt current | 15,818 | 8,406 | |||
Long-term debt | 128,551 | 43,466 | |||
Deferred revenue | 7,715 | ||||
Other long-term liabilities | |||||
Net debt | (207,600) | 2,765 | |||
| Cash flow | |||||
Cash from operating activities | 139,803 | (93,786) | |||
CAPEX | (5,614) | (2,887) | |||
Cash from investing activities | (138,395) | (148,650) | |||
Cash from financing activities | 21,037 | 479 | |||
FCF | (173,850) | (125,424) | |||
| Balance | |||||
Cash | 351,969 | 45,157 | |||
Long term investments | 3,950 | ||||
Excess cash | 345,518 | 49,107 | |||
Stockholders' equity | (194,772) | (190,339) | |||
Invested Capital | 520,986 | 428,829 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 33,050 | 31,293 | |||
Price | 15.09 11.61% | 13.52 -21.03% | |||
Market cap | 498,729 17.88% | 423,086 -20.85% | |||
EV | 291,129 | 425,851 | |||
EBITDA | (100,205) | (97,248) | |||
EV/EBITDA | |||||
Interest | 2,632 | ||||
Interest/NOPBT | |||||